Paid Clinical Trials Stamford

Discover 1,036 paid clinical trials in Stamford, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,036

TebapivatA Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Recruiting

PHASE2

Sponsor:

Agios Pharmaceuticals, Inc.

Location:

Long Island City NY, New Haven CT, Durham NC, Skokie ILshow 5 more

Code:

NCT05490446

Conditions

Myelodysplastic Syndromes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tebapivat

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Stamford CT, Port Jefferson Station NY, Patchogue NY, Boston MAshow 59 more

Code:

NCT05156281

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

LY3556050A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting

PHASE2

Sponsor:

Eli Lilly and Company

Location:

Port Jefferson Station NY, Hamden CT, East Brunswick NJ, Philadelphia PAshow 29 more

Code:

NCT06074562

Conditions

Diabetic Peripheral Neuropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LY3556050

Placebo

Crenolanib vs. MidostaurinStudy of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting

PHASE3

Sponsor:

Arog Pharmaceuticals, Inc.

Location:

Bronx NY, Hackensack NJ, New York NY, New Haven CTshow 17 more

Code:

NCT03258931

Conditions

Newly Diagnosed FLT3 Mutated AML

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Crenolanib

Midostaurin

Cytarabine

Duanorubicin

Opioid Package PrototypeOpioid Package Prototype (OPP)

Recruiting

Sponsor:

UConn Health

Location:

Farmington CT

Code:

NCT04598074

Conditions

Opioid Use

Opioid Prescribing, Dispensing, and Patient Use

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Opioid Package Prototype (OPP)

Usual Care (standard amber vial)

Single vs. MultipleComparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

Recruiting

Sponsor:

Weill Medical College of Cornell University

Location:

Englewood NJ, Queens NY, Ridgewood NJ, New York NYshow 45 more

Code:

NCT04124120

Conditions

Heart Diseases

Coronary Artery Disease

Coronary Artery Bypass Grafting

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Single arterial graft

Multiple arterial grafting

Local Ablative TherapyA Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Recruiting

PHASE2

Sponsor:

Memorial Sloan Kettering Cancer Center

Location:

Harrison NY, Commack NY, Uniondale NY, Montvale NJshow 5 more

Code:

NCT05429320

Conditions

Non-small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

Nsclc

NSCLC Stage IV

Minimal Residual Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Local ablative therapy

Blood collection to assess for ctDNA

Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Norwalk CT, New York NY, New Brunswick NJ, Philadelphia PAshow 29 more

Code:

NCT05455320

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talquetamab

Daratumumab

Pomalidomide

Dexamethasone

NNC0487-0111A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting

PHASE2

Sponsor:

Novo Nordisk A/S

Location:

Waterbury CT, Albany NY, Hyattsville MD, Oxon Hill MDshow 20 more

Code:

NCT06542874

Conditions

Type 2 Diabetes (T2D)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

NNC0487-0111 subcutanous

Placebo (NNC0487-0111 subcutanous)

NNC0487-0111 oral

Placebo (NNC0487-0111 oral)

EP0062Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting

PHASE1

PHASE2

Sponsor:

Ellipses Pharma

Location:

New Haven CT, Boston MA, Fairfax VA, Detroit MIshow 3 more

Code:

NCT05573126

Conditions

Hormone Receptor-positive Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vosilasarm

Elacestrant

Everolimus